ATE488765T1 - Verfahren zum frühen nachweis einer nierenkrankheit und -verletzung - Google Patents

Verfahren zum frühen nachweis einer nierenkrankheit und -verletzung

Info

Publication number
ATE488765T1
ATE488765T1 AT05755309T AT05755309T ATE488765T1 AT E488765 T1 ATE488765 T1 AT E488765T1 AT 05755309 T AT05755309 T AT 05755309T AT 05755309 T AT05755309 T AT 05755309T AT E488765 T1 ATE488765 T1 AT E488765T1
Authority
AT
Austria
Prior art keywords
ngal
renal
injury
blood serum
early
Prior art date
Application number
AT05755309T
Other languages
German (de)
English (en)
Inventor
Prasad Devarajan
Jonathan Barasch
Original Assignee
Childrens Hosp Medical Center
Univ Columbia
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35449446&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE488765(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Childrens Hosp Medical Center, Univ Columbia filed Critical Childrens Hosp Medical Center
Application granted granted Critical
Publication of ATE488765T1 publication Critical patent/ATE488765T1/de

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/573—Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/82—Translation products from oncogenes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/34—Genitourinary disorders
    • G01N2800/347—Renal failures; Glomerular diseases; Tubulointerstitial diseases, e.g. nephritic syndrome, glomerulonephritis; Renovascular diseases, e.g. renal artery occlusion, nephropathy
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • General Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Measurement Of The Respiration, Hearing Ability, Form, And Blood Characteristics Of Living Organisms (AREA)
  • Transplanting Machines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AT05755309T 2004-06-07 2005-06-07 Verfahren zum frühen nachweis einer nierenkrankheit und -verletzung ATE488765T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US57766204P 2004-06-07 2004-06-07
US11/096,113 US20050272101A1 (en) 2004-06-07 2005-03-31 Method for the early detection of renal injury
PCT/US2005/019951 WO2005121788A2 (en) 2004-06-07 2005-06-07 Method for the early detection of renal disease and injury

Publications (1)

Publication Number Publication Date
ATE488765T1 true ATE488765T1 (de) 2010-12-15

Family

ID=35449446

Family Applications (1)

Application Number Title Priority Date Filing Date
AT05755309T ATE488765T1 (de) 2004-06-07 2005-06-07 Verfahren zum frühen nachweis einer nierenkrankheit und -verletzung

Country Status (10)

Country Link
US (7) US20050272101A1 (enExample)
EP (2) EP2264459B1 (enExample)
JP (1) JP5054525B2 (enExample)
CN (1) CN101027556B (enExample)
AT (1) ATE488765T1 (enExample)
AU (1) AU2005253142B2 (enExample)
CA (1) CA2569599C (enExample)
DE (1) DE602005024810D1 (enExample)
ES (1) ES2717900T3 (enExample)
WO (1) WO2005121788A2 (enExample)

Families Citing this family (86)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3167935B1 (en) 2003-05-01 2018-07-18 Cornell Research Foundation, Inc. Method and carrier complexes for delivering molecules to cells
US20050272101A1 (en) * 2004-06-07 2005-12-08 Prasad Devarajan Method for the early detection of renal injury
CA2565701A1 (en) * 2004-05-06 2005-11-17 Jonathan M. Barasch Ngal for reduction and amelioration of ischemic and nephrotoxic injuries
DK1831699T3 (da) * 2004-12-20 2010-03-15 Antibodyshop As Bestemmelse af neutrofil gelatine-associeret lipocalin (NGAL) som en diagnostisk markør for nyresygdomme
US20070037232A1 (en) 2005-03-31 2007-02-15 Barasch Jonathan M Detection of NGAL in chronic renal disease
EP3725324A1 (en) 2005-09-16 2020-10-21 Cornell Research Foundation, Inc. Aromatic-cationic peptide for use in a method for reducing cd36 expression
US20080090304A1 (en) * 2006-10-13 2008-04-17 Barasch Jonathan Matthew Diagnosis and monitoring of chronic renal disease using ngal
US10716749B2 (en) * 2005-11-03 2020-07-21 Palo Alto Investors Methods and compositions for treating a renal disease condition in a subject
US7662578B2 (en) 2006-04-21 2010-02-16 Children's Hospital Medical Center Method and kit for the early detection of impaired renal status
US20080090765A1 (en) * 2006-05-25 2008-04-17 The Trustees Of Columbia University In The City Of New York Compositions for modulating growth of embryonic and adult kidney tissue and uses for treating kidney damage
PL2035835T3 (pl) * 2006-05-30 2012-05-31 Antibodyshop As Sposoby szybkiej oceny ciężkości urazu
WO2008017306A1 (en) * 2006-08-07 2008-02-14 Antibodyshop A/S Diagnostic test to exclude significant renal injury
US7842472B2 (en) 2006-11-14 2010-11-30 Alere International Methods and compositions for monitoring and risk prediction in cardiorenal syndrome
EP2095106B1 (en) * 2006-11-14 2013-03-20 Alere San Diego, Inc. Methods and compositions for diagnosis and prognosis of renal artery stenosis
EP2137538B1 (en) * 2007-03-21 2014-04-09 Bioporto Diagnostics A/s Diagnostic test for renal injury
US20090124022A1 (en) * 2007-10-19 2009-05-14 Abbott Laboratories Antibodies that bind to mammalian ngal and uses thereof
EP2225268B1 (en) * 2007-10-19 2012-08-29 Abbott Laboratories Immunoassays and kits for the detection of ngal
US8846036B2 (en) * 2007-10-19 2014-09-30 Abbott Laboratories Antibodies that bind to mammalian NGAL and uses thereof
US20090123946A1 (en) * 2007-10-19 2009-05-14 Abbott Laboratories Immunoassays and kits for the detection of ngal
WO2009059259A2 (en) * 2007-10-31 2009-05-07 Children's Hospital Medical Center Detection of worsening renal disease in subjects with systemic lupus erythematosus
EP2215481B2 (en) * 2007-11-15 2017-01-18 Bioporto Diagnostics A/S Diagnostic use of individual molecular forms of a biomarker
EP2712620A1 (en) 2008-02-07 2014-04-02 Cornell University Methods for Preventing or Treating Insulin Resistance
CN107802821A (zh) * 2008-02-26 2018-03-16 康奈尔大学 用于防止和治疗急性肾损伤的方法
EP2257813A4 (en) * 2008-03-12 2011-11-02 Univ Columbia NGAL WITH HIGH MOLECULAR WEIGHT AS BIOMARKER FOR CHRONIC KIDNEY DISEASE
GB0807214D0 (en) * 2008-04-21 2008-05-28 Belfast Health And Social Care Biomarkers
US7977110B2 (en) * 2008-06-02 2011-07-12 Children's Hospital Medical Center Method for distinguishing between kidney dysfunctions
US20100122355A1 (en) * 2008-07-16 2010-05-13 Neal Paragas Transgenic Reporter Mouse and Method for Use
JP2012501456A (ja) * 2008-08-28 2012-01-19 アスチュート メディカル，インコーポレイテッド 腎損傷および腎不全の診断および予後のための方法および組成物
CA2735590A1 (en) * 2008-08-29 2010-03-04 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of renal injury and renal failure
EP2767833A3 (en) * 2008-10-21 2014-12-17 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of renal injury and renal failure
WO2010048346A1 (en) 2008-10-21 2010-04-29 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of renal injury and renal failure
US20100105150A1 (en) * 2008-10-24 2010-04-29 Abbott Laboratories Isolated human autoantibodies to neutrophil gelatinase-associated lipocalin (ngal) and methods and kits for the detection of human autoantibodies to ngal
WO2010054025A1 (en) * 2008-11-05 2010-05-14 Abbott Laboratories Neutrophil gelatinase-associated lipocalin (ngal) protein isoforms enriched from urine and recombinant chinese hamster ovary (cho) cells and related compositions, antibodies, and methods of enrichment, analysis and use
CN104330574B (zh) 2008-11-10 2017-04-12 阿斯图特医药公司 用于诊断和预后肾损伤和肾衰竭的方法和组合物
US20100124829A1 (en) * 2008-11-17 2010-05-20 Hon Hai Precision Industry Co., Ltd. Electrical connector with a printed circuit board mounted thereon
US9476880B2 (en) 2008-11-21 2016-10-25 Future Medical Diagnostics Co., Ltd. Methods, devices and kits for detecting or monitoring acute kidney injury
EP2364370B1 (en) * 2008-11-22 2014-09-03 Astute Medical, Inc. Methods for prognosis of acute renal failure
US9229010B2 (en) 2009-02-06 2016-01-05 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of renal injury and renal failure
EP3244213A1 (en) * 2009-02-06 2017-11-15 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of renal injury and renal failure
US20100233740A1 (en) * 2009-02-12 2010-09-16 Jonathan Barasch Use of urinary ngal to distinguish kidney disease and predict mortality in subjects with cirrhosis
US20100233739A1 (en) * 2009-02-12 2010-09-16 Jonathan Barasch Use of urinary ngal to diagnose unilateral and bilateral urinary obstruction
EP3563862B1 (en) 2009-03-20 2021-05-05 The General Hospital Corporation d/b/a Massachusetts General Hospital D-arg-2'6'-dimethyltyrosine-lys-phe-nh2 for use in the prevention of secondary complications of burn injuries
ES2516717T3 (es) * 2009-05-26 2014-10-31 Universidad De Salamanca Proteína activadora de GM2 en orina como marcador de fallo renal agudo o de riesgo de desarrollar fallo renal agudo
KR20120061863A (ko) 2009-08-07 2012-06-13 아스튜트 메디컬 인코포레이티드 신장 손상 및 신부전증의 진단과 예후를 위한 방법 및 조성물
CA2770688C (en) * 2009-08-12 2018-06-05 Cornell University Methods for preventing or treating metabolic syndrome
SI3708178T1 (sl) 2009-08-24 2024-01-31 Stealth Biotherapeutics Inc. Peptid za uporabo pri preprečevanju ali zdravljenju degeneracije makule
US20120315649A1 (en) * 2009-08-28 2012-12-13 Astute Medical ,Inc. a corporation Methods and compositions for diagnosis and prognosis of renal injury and renal failure
EP3603658B1 (en) 2009-10-05 2025-01-08 Cornell University Peptide for use in the treatment of heart failure resulting from hypertrophic cardiomyopathy
WO2011053832A1 (en) * 2009-10-29 2011-05-05 The Trustees Of Columbia University In The City Of New York Use of urinary ngal to diagnose sepsis in very low birth weight infants
MX340078B (es) 2009-11-07 2016-06-24 Astute Medical Inc Metodos y composiciones para el diagnostico y pronostico de daño renal y falla renal.
MX342967B (es) 2009-12-20 2016-10-19 Astute Medical Inc Metodos y composiciones para la diagnosis y prognosis de lesion renal y falla renal.
CN102791885B (zh) 2010-02-05 2015-09-09 阿斯图特医药公司 用于肾损伤和肾衰竭的诊断及预后的方法和组合物
EP2539712A4 (en) 2010-02-26 2013-09-18 Astute Medical Inc METHODS AND COMPOSITIONS FOR DIAGNOSIS AND PROGNOSIS OF RENAL INJURY AND RENAL FAILURE
GB2478520A (en) * 2010-03-02 2011-09-14 Binding Site Group Ltd Kidney prognostic assay
US20110229921A1 (en) * 2010-03-18 2011-09-22 Abbott Laboratories METHODS OF ASSAYING URINARY NEUTROPHIL GELATINASE-ASSOCIATED LIPOCALIN (uNGAL) IN THE PROGNOSIS OF CADAVERIC KIDNEY TRANSPLANT FUNCTION IN A PATIENT, INCLUDING A PATIENT DIAGNOSED WITH DELAYED GRAFT FUNCTION (DGF), A METHOD OF ASSAYING uNGAL IN THE ASSESSMENT OF RISK OF DGF IN A PATIENT DIAGNOSED WITH EARLY GRAFT FUNCTION (EGF), AND RELATED KITS
CN102072960A (zh) * 2010-03-29 2011-05-25 武汉生之源生物科技有限公司 一种样本中中性粒细胞明胶酶相关脂质运载蛋白的检测方法
US9684002B2 (en) * 2010-05-10 2017-06-20 Intrinsic Lifesciences Llc Markers for acute kidney injury
JP2013529907A (ja) 2010-05-24 2013-07-25 ザ トラスティーズ オブ コロンビア ユニヴァーシティ イン ザ シティ オブ ニューヨーク Ｎｇａｌタンパク質変異体及びその使用
EP2397559A1 (en) * 2010-06-17 2011-12-21 Max-Delbrück-Centrum Für Molekulare Medizin Stage-specific biomarkers for the diagnosis of acute kidney injury
IN2012MN02812A (enExample) 2010-06-23 2015-05-22 Astute Medical Inc
NZ605698A (en) 2010-06-23 2015-03-27 Astute Medical Inc Methods and compositions for diagnosis and prognosis of renal injury and renal failure
ES2398646T3 (es) * 2010-07-24 2013-03-20 F. Hoffmann-La Roche Ag Estabilización de la interleuquina-6 en soluciones de suero
CA2811438A1 (en) * 2010-10-07 2012-04-12 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of renal injury and renal failure
CN102253217B (zh) * 2011-04-07 2013-08-07 武汉生之源生物科技有限公司 一种胶乳颗粒增强型中性粒细胞明胶酶相关脂质运载蛋白检测试剂盒
CN102243241A (zh) * 2011-04-07 2011-11-16 武汉生之源生物科技有限公司 一种匀相溶胶颗粒型中性粒细胞明胶酶相关脂质运载蛋白测定试剂盒及其制备方法
NL2007112C2 (en) 2011-07-14 2013-01-15 Brainlabs B V Novel diagnostic method for diagnosing depression and monitoring therapy effectiveness.
CA2846602A1 (en) * 2011-08-26 2013-03-28 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of renal injury and renal failure
US20130062516A1 (en) * 2011-09-09 2013-03-14 Hsien-Shou Kuo Diganosis of a renal disease by oxygen and hydrogen isotopes in a biological sample
CA2845117A1 (en) * 2011-09-14 2013-03-21 Basf Se Means and methods for assessing kidney toxicity
KR20140076571A (ko) * 2011-09-22 2014-06-20 유니버시다드 데 로스 안데스 급성 신장 손상의 조기 모니터링, 진단 및/또는 예후 방법
EP3540440B1 (en) 2011-12-08 2022-09-28 Astute Medical, Inc. Methods and uses for evaluating renal injury and renal status
JP5988199B2 (ja) * 2012-05-29 2016-09-07 学校法人順天堂 ＩｇＡ腎症診断法
GB201210587D0 (en) * 2012-06-14 2012-08-01 Belfast Health And Social Care Trust Predictive biomarker
EP2925337B1 (en) 2012-11-21 2019-07-03 The Trustees of Columbia University in the City of New York Mutant ngal proteins and uses thereof
JP6681195B2 (ja) 2013-01-17 2020-04-15 アスチュート メディカル，インコーポレイテッド 腎損傷および腎不全の診断および予後診断のための方法ならびに組成物
EP3022314B1 (en) 2013-07-15 2021-05-19 President and Fellows of Harvard College Assays for antimicrobial activity and applications thereof
CN104198732B (zh) * 2014-08-28 2015-08-19 宁波瑞源生物科技有限公司 一种中性粒细胞明胶酶相关脂质运载蛋白含量检测试剂盒
CN104849469A (zh) * 2015-04-16 2015-08-19 广州市达瑞生物技术股份有限公司 一种检测ngal含量的试剂盒及其制备方法
CL2015003047A1 (es) 2015-10-15 2016-06-17 Univ Chile Método ex vivo para detectar precozmente injuria renal aguda en pacientes críticos, que comprende la mediciom en una muestra de tres proteinas como biomarcadores, factor de crecimiento fibroblástico 23, klotho y eritropoyetina
AU2017277305A1 (en) 2016-06-06 2018-12-20 Astute Medical, Inc. Management of acute kidney injury using insulin-like growth factor-binding protein 7 and tissue inhibitor of metalloproteinase 2
CN110431422A (zh) 2017-02-06 2019-11-08 机敏医药股份有限公司 用于肾损伤和肾衰竭的诊断和预后的方法和组合物
CN110229214B (zh) * 2018-03-05 2022-03-18 四川大学华西医院 一种外泌体缓释多肽水凝胶及其制备方法和用途
JPWO2020080491A1 (ja) * 2018-10-17 2021-09-09 Kagami株式会社 血液中のクレアチニン量に基づく腎機能検査結果の妥当性を検定する方法
US11350887B2 (en) 2019-08-07 2022-06-07 Fresenius Medical Care Holdings, Inc. Systems and methods for detection of potential health issues
EP4330685A2 (en) * 2021-04-30 2024-03-06 Roche Diagnostics GmbH Ngal marker panels for early detection of sepsis
JP7866787B2 (ja) * 2024-03-15 2026-05-28 台北医学大学 急性腎臓病予測方法及び予測システム

Family Cites Families (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5622871A (en) * 1987-04-27 1997-04-22 Unilever Patent Holdings B.V. Capillary immunoassay and device therefor comprising mobilizable particulate labelled reagents
US3635091A (en) * 1970-08-31 1972-01-18 Frederick D Linzer Midstream urine specimen and fractional fluid collectors
IT1074038B (it) * 1976-08-05 1985-04-17 Simes Esteri della epinina
US4376110A (en) * 1980-08-04 1983-03-08 Hybritech, Incorporated Immunometric assays using monoclonal antibodies
US4357343A (en) * 1981-06-26 1982-11-02 Baxter Travenol Laboratories, Inc. Nutritional composition for management of renal failure
US4376100A (en) * 1981-11-23 1983-03-08 The Dow Chemical Company Lithium halide brine purification
US4632901A (en) * 1984-05-11 1986-12-30 Hybritech Incorporated Method and apparatus for immunoassays
US4640909A (en) * 1985-05-07 1987-02-03 J. T. Baker Chemical Company Bonded phase of silica and carboalkoxyalkyl silanes for solid phase extraction
US4870007A (en) * 1987-12-18 1989-09-26 Eastman Kodak Company Immobilized biotinylated receptor in test device, kit and method for determining a ligand
US5939272A (en) * 1989-01-10 1999-08-17 Biosite Diagnostics Incorporated Non-competitive threshold ligand-receptor assays
US5273743A (en) * 1990-03-09 1993-12-28 Hybritech Incorporated Trifunctional antibody-like compounds as a combined diagnostic and therapeutic agent
JP2912413B2 (ja) * 1990-03-28 1999-06-28 東亜医用電子株式会社 粒度分布作成方法
US5405832A (en) * 1991-11-27 1995-04-11 Immtech International Inc. Method of treating non-streptococcal bacterial infections
US5273961A (en) * 1992-09-22 1993-12-28 Genentech, Inc. Method of prophylaxis of acute renal failure
SE9401351D0 (sv) * 1994-04-21 1994-04-21 Venge A method for diagnosis
US5552313A (en) * 1994-11-21 1996-09-03 Kansas University DNA encoding mouse phosphotriesterase-related protein
US5814462A (en) * 1995-10-02 1998-09-29 The Trustees Of Columbia University In The City Of New York Biochemical markers of ischemia
US5750345A (en) * 1995-10-31 1998-05-12 Evanston Hospital Corporation Detection of human α-thalassemia mutations and their use as predictors of blood-related disorders
US5627034A (en) * 1995-12-05 1997-05-06 Wisconsin Alumni Research Foundation Assay for carcinoma proliferative status by measuring NGAL expression level
JP4602482B2 (ja) * 1996-05-24 2010-12-22 バイオジェン・アイデック・エムエイ・インコーポレイテッド 組織再生のモジュレーター
US5945294A (en) * 1996-11-26 1999-08-31 Heska Corporation Method to detect IgE
JP3334558B2 (ja) * 1997-04-23 2002-10-15 富士レビオ株式会社 酵素免疫測定方法及び試験片
KR100546223B1 (ko) * 1997-04-30 2006-01-26 마루하 주식회사 허혈성질환의 검출 또는 예지방법과 그 검출용키트
US6020163A (en) * 1997-08-06 2000-02-01 Zymogenetics, Inc. Lipocalin homolog
US6242246B1 (en) * 1997-12-15 2001-06-05 Somalogic, Inc. Nucleic acid ligand diagnostic Biochip
US6500627B1 (en) * 1998-02-03 2002-12-31 The Trustees Of Columbia University In The City Of New York Methods for predicting pregnancy outcome in a subject by HCG assay
US6309888B1 (en) * 1998-09-04 2001-10-30 Leuven Research & Development Vzw Detection and determination of the stages of coronary artery disease
AUPP784398A0 (en) * 1998-12-21 1999-01-21 Monash University Kidney disease detection and treatment
US6114123A (en) * 1999-06-14 2000-09-05 Incyte Pharmaceuticals, Inc. Lipocalin family protein
AU5330200A (en) * 1999-06-18 2001-01-09 Michigan State University Method and apparatus for the detection of volatile products in a sample
US6762032B1 (en) * 1999-08-23 2004-07-13 Biocrystal, Ltd. Compositions, assay kits, and methods for use related to a disease condition comprising multiple sclerosis and/or a pro-MS immune response
US20020160495A1 (en) * 2000-09-20 2002-10-31 University Of Medicine And Dentistry Soluble ischemia activated protein
AU2001293964B2 (en) * 2000-10-03 2007-06-14 Rowett Research Institute Method of assaying pyrrole-containing biological compounds
US7153660B2 (en) * 2000-10-13 2006-12-26 Children's Medical Center Corporation Non-invasive enzyme screen for tissue remodelling-associated conditions
FI20010019A7 (fi) * 2001-01-05 2002-07-06 Biohit Oyj Menetelmä atrofisen gastriitin diagnostisoimiseksi
US7172873B2 (en) * 2001-03-28 2007-02-06 Heska Corporation Methods of detecting early renal disease in animals
US7713705B2 (en) * 2002-12-24 2010-05-11 Biosite, Inc. Markers for differential diagnosis and methods of use thereof
US20040203083A1 (en) * 2001-04-13 2004-10-14 Biosite, Inc. Use of thrombus precursor protein and monocyte chemoattractant protein as diagnostic and prognostic indicators in vascular diseases
EP1322957B1 (en) * 2001-05-04 2009-08-12 Biosite Incorporated Diagnostic markers of acute coronary syndromes and methods of use thereof
US6767733B1 (en) * 2001-10-10 2004-07-27 Pritest, Inc. Portable biosensor apparatus with controlled flow
US6986995B2 (en) * 2002-02-28 2006-01-17 Prometheus Laboratories, Inc. Methods of diagnosing liver fibrosis
US6847451B2 (en) * 2002-05-01 2005-01-25 Lifescan, Inc. Apparatuses and methods for analyte concentration determination
GB0215509D0 (en) 2002-07-04 2002-08-14 Novartis Ag Marker genes
AU2003247303A1 (en) * 2002-07-17 2004-02-02 Index Pharmaceuticals Ab Antisense compounds, methods and compositions for treating ngal-related inflammatory disorders
CN1417583A (zh) * 2002-11-27 2003-05-14 复旦大学 一种检测辐射肾性骨矿物盐损伤方法
DE602004022150D1 (de) * 2003-03-27 2009-09-03 Childrens Hosp Medical Center Verfahren und kit zum nachweis des frühstadiums einer nierentubuluszellenverletzung
CA2565701A1 (en) * 2004-05-06 2005-11-17 Jonathan M. Barasch Ngal for reduction and amelioration of ischemic and nephrotoxic injuries
US20050272101A1 (en) * 2004-06-07 2005-12-08 Prasad Devarajan Method for the early detection of renal injury
DK1831699T3 (da) * 2004-12-20 2010-03-15 Antibodyshop As Bestemmelse af neutrofil gelatine-associeret lipocalin (NGAL) som en diagnostisk markør for nyresygdomme
PL2035835T3 (pl) * 2006-05-30 2012-05-31 Antibodyshop As Sposoby szybkiej oceny ciężkości urazu
EP2137538B1 (en) * 2007-03-21 2014-04-09 Bioporto Diagnostics A/s Diagnostic test for renal injury
US7977110B2 (en) * 2008-06-02 2011-07-12 Children's Hospital Medical Center Method for distinguishing between kidney dysfunctions
WO2013103896A1 (en) 2012-01-06 2013-07-11 Mayo Foundation For Medical Education And Research Treating cardiovascular or renal diseases

Also Published As

Publication number Publication date
EP1766395A4 (en) 2008-03-19
EP1766395A2 (en) 2007-03-28
US20110143456A1 (en) 2011-06-16
AU2005253142B2 (en) 2011-09-29
CN101027556B (zh) 2013-03-13
US20100028919A1 (en) 2010-02-04
EP2264459A2 (en) 2010-12-22
DE602005024810D1 (de) 2010-12-30
US20080014604A1 (en) 2008-01-17
EP2264459A3 (en) 2011-02-16
JP5054525B2 (ja) 2012-10-24
CN101027556A (zh) 2007-08-29
US20050272101A1 (en) 2005-12-08
JP2008501979A (ja) 2008-01-24
US20090142774A1 (en) 2009-06-04
WO2005121788A2 (en) 2005-12-22
ES2717900T3 (es) 2019-06-26
US20100047837A1 (en) 2010-02-25
EP1766395B2 (en) 2018-09-19
EP1766395B1 (en) 2010-11-17
EP2264459B1 (en) 2019-01-02
WO2005121788A3 (en) 2006-05-11
AU2005253142A1 (en) 2005-12-22
CA2569599C (en) 2018-10-23
CA2569599A1 (en) 2005-12-22
US20110244489A1 (en) 2011-10-06

Similar Documents

Publication Publication Date Title
DE602005024810D1 (de) Verfahren zum frühen nachweis einer nierenkrankheit und -verletzung
BRPI0408802A (pt) método e kit para detectar o inìcio precoce de lesão de células tubulares renais
DK1421215T3 (da) Fremgangsmåder til evaluering af patologiske tilstande under anvendelse af ekstracellulært RNA
AR107561A2 (es) Ensayo elisa para la detección de vegf
WO2001042502A3 (en) Methods for disease detection
WO2006073682A3 (en) Diagnostic test
ATE438737T1 (de) Verfahren für den nachweis von erkrankungen
ATE432470T1 (de) Verfahren zur unterscheidung des reizkolons von der entzündlichen darmerkrankung (inflammatory bowel disease, ibd) und zur überwachung von patienten mit ibd unter verwendung von endogenem gesamt-lactoferrin als marker
ATE529743T1 (de) Verfahren und kits zur tumorigenizitätsdiagnose
WO2009014342A3 (en) Markers and kit for diagnosis of alzheimer's disease
ATE336003T1 (de) Verfahren zur sepsisdiagnose durch bestimmung von anti-asialo-gangliosid-antikörpern
WO2002016947A3 (en) Methods and kits for separation and detection of proteins in biological samples
Strak et al. A study of lichen planus and its association with hepatitis C infection
BR0111975A (pt) Fator, composição, veìculo, ligando, kits de diagnósticos, processos para detectar uma prpsc em uma amostra, e para remover prpsc de material biológico, método para diagnosticar encefalopatias espongiformes humanas transmissìveis e encefalopatias de prìons de animais, e, uso de um fator
WO2003099107A3 (en) Methods and kits for the detection of renal cell carcinoma in a biological fluid of a patient
BR0308095A (pt) Teste para anticorpos anti-ingap
WO2006089219A3 (en) Neoepitope detection of disease using protein arrays
ATE433991T1 (de) Morbus-crohn-antikörperepitoppeptid und reagens zum testen auf morbus crohn
DE60115453D1 (de) Verfahren zur detektion der apoptose durch ermittlung von cytochrom c als apoptosespezifischem marker, der durch zelluläre ausschüttungsvorgänge ins extrazelluläre medium abgegeben wird
WO2007060240A3 (fr) Procede pour la mise en evidence de la presence ou de l ' absence de marquers (eef1a1 ou mark3 ) associes a la presence et/ou a la chimiosensibilite des tumeurs
DE602006002311D1 (de) Biomarker zur Reaktionsüberwachung von CdK-Hemmern in der Klinik
DE602005023973D1 (de) Verfahren zur diagnose von chronischem stress und verwandten erkrankungen
UA4190U (uk) Спосіб діагностики імунодефіцитних захворювань апоптогенного генезу
Ghosh et al. Biosensor Incorporating Cell Barrier Architectures For Screening Cancer
WO2006089422A8 (en) Protein and its use in diagnosing alzheimer's disease

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties